{
    "Project Title": "Not Available",
    "Sponsor": "Merck",
    "Study Number": "Not Available",
    "Protocol Version and Date": "Version Date: 02/09/2020",
    "Study Title": "Not Available",
    "Phase": "Not Available",
    "Therapeutic Area": "Renal Cell Carcinoma",
    "Number of Patients": "17",
    "Number of Sites": "Not Available",
    "Indication": "Renal cell carcinoma with clear cell component",
    "Duration of Treatment": "Not Available",
    "Schedule of Assessments": "Trial Flow Chart (Section 6.0)",
    "questionnaires": [
        {
            "longName": "Quality of Life Assessment",
            "shortName": "FKSI-19",
            "type": "PRO",
            "questionnaireSchedule": "Baseline, halfway through treatment (Cycle 3 Day 1), and after 12 weeks of treatment.",
            "questionnaireTiming": [
                "Day:   (Treatment Cycle/Title:  ) (Trial Phase:  ): -3 to 1   (Baseline (Visit 2)a,b  )",
                "Day:   (Treatment Cycle/Title:  ) (Trial Phase:  ): 43   (3  )",
                "Day:   (Treatment Cycle/Title:  ) (Trial Phase:  ): Within 14 days of last dose of lenvatinib   (Post-Treatment Phase  )"
            ]
        },
        {
            "longName": "Frailty Assessment",
            "shortName": "Fried Frailty score",
            "type": "ClinRO",
            "questionnaireSchedule": "Baseline, halfway through treatment (Cycle 3 Day 1), and after 12 weeks of treatment.",
            "questionnaireTiming": [
                "Day:   (Treatment Cycle/Title:  ) (Trial Phase:  ): -28 to 1   (Screening (Visit 1)a,b  ) (Pre-treatment Phase  )",
                "Day:   (Treatment Cycle/Title:  ) (Trial Phase:  ): Within 14 days of last dose of lenvatinib   (Post-Treatment Phase  )",
                "Day:   (Treatment Cycle/Title:  ) (Trial Phase:  ): -3 to 1   (Baseline (Visit 2)a,b  )",
                "Day:   (Treatment Cycle/Title:  ) (Trial Phase:  ): 43   (3  )"
            ]
        }
    ]
}